Advertisement

Topics

Ambu A/S: Annual Report 2016/17 (Earnings Release)

03:05 EST 9 Nov 2017 | GlobalNewsWire (2014)

This article has expired, however you can still download the PDF.
Preview:
Ambu ends four-year strategy period with solid results: 14% organic growth, an EBIT margin of 19.1% and free cash flows of DKK 321m."It's highly satisfactory that we conclude our 2017 strat...

Other Sources for this Article

NEXT ARTICLE

More From BioPortfolio on "Ambu A/S: Annual Report 2016/17 (Earnings Release)"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Mergers & Acquisitions
Commercial and market reports on mergers and acquisitions in the biotechnology, pharmaceutical, medical device and life-science industries. Mergers and acquisitions (abbreviated M&A;) is an aspect of corporate strategy, corporate finance and manageme...

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...